Open AccessJournal Article
Establishment and characterization of a human prostatic carcinoma cell line (PC-3).
1.7K
TL;DR: The establishment, characterization, and tumorigenicity of a new epithelial cell line (PC-3) from a human prostatic adenocarcinoma metastatic to bone is reported, which should be useful in investigating the biochemical changes in advanced prostatic cancer cells and in assessing their response to chemotherapeutic agents.
read more
Abstract: The establishment, characterization, and tumorigenicity of a new epithelial cell line (PC-3) from a human prostatic adenocarcinoma metastatic to bone is reported The cultured cells show anchorage-independent growth in both monolayers and in soft agar suspension and produce subcutaneous tumors in nude mice Culture of the transplanted tumor yielded a human cell line with characteristics identical to those used initially to produce the tumor PC-3 has a greatly reduced dependence upon serum for growth when compared to normal prostatic epithelial cells and does not respond to androgens, glucocorticoids, or epidermal or fibroblast gowth factors Karyotypic analysis by quinacrine banding revealed the cells to be completely aneuploid with a modal chromosome number in the hypotriploid range At least 10 distinctive marker chromosomes were identified The overall karyotype as well as the marker chromosomes are distinct from those of the HeLa cell Electron microscopic studies revealed many features common to neoplastic cells of epithelial origin including numerous microvilli, junctional complexes, abnormal nuclei and nucleoli, abnormal mitochondria, annulate lamellae, and lipoidal bodies Overall, the functional and morphologic characteristics of PC-3 are those of a poorly-differentiated adenocarcinoma These cells should be useful in investigating the biochemical changes in advanced prostatic cancer cells and in assessing their response to chemotherapeutic agents
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Characterization of a fetal urogenital sinus mesenchymal cell line U4F: Secretion of a negative growth regulatory activity
TL;DR: Physicochemical, immunological, and biological properties showed the activity is identical in conditioned media from urogenital sinus organ cultures, U4F spheroids, and U4f1 monolayers, which means this activity cannot be ascribed to previously characterized negative growth factors.
34
Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells
Ana B. Fernández-Martínez,Ana M. Bajo,Manuel Sánchez-Chapado,Juan C. Prieto,María J. Carmena +4 more
TL;DR: The expression of related biomarker proteins (cyclin D1, metalloproteinases MMP‐2 and M MP‐9, and E‐cadherin) in human androgen‐dependent (LNCaP) and independent (PC3) prostate cancer cells are evaluated.
34
Prostate-derived soluble factors block osteoblast differentiation in culture.
TL;DR: Results show that conditioned medium from PC‐3 cells (PC‐3 CM) stimulates osteoblast proliferation and inhibits both alkaline phosphatase activity and the mineralization process, measured as calcium accumulation (late differentiation marker), which suggests that both processes occur in a nonsimultaneous fashion.
34
A d-amino acid containing peptide as a potent, noncovalent inhibitor of α5β1 integrin in human prostate cancer invasion and lung colonization
TL;DR: It is reported that d-stereoisomer replacement of histidine and cysteine in PHSCN produces a highly potent derivative, PhScN, which represents a potent new family of therapeutic agents targeting metastasis by DTC’s to prevent parallel progression in prostate cancer.
34
Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene.
Valery Bliskovsky,Edward S. Ramsay,John D. Scott,Wendy Dubois,Wei Shi,Shuling Zhang,Xiaolan Qian,Douglas R. Lowy,Beverly A. Mock +8 more
TL;DR: These studies identify Frap as a candidate tumor suppressor gene, in contrast to many reports that have focused on its prooncogenic properties, and suggests that FRAP antagonists may not be appropriate for the treatment of plasma cell tumors.
34